RESEARCHER PROFILE

Markus Hinder

← Back to Hochschule Fresenius

M

Hochschule Fresenius

Pharmaceutical Economics and PolicyPharmaceutical industry and healthcareBlood Pressure and Hypertension StudiesRenin-Angiotensin System StudiesComputational Drug Discovery Methods

Markus Hinder works in Pharmaceutical Economics and Policy, Pharmaceutical industry and healthcare, Blood Pressure and Hypertension Studies, Renin-Angiotensin System Studies, Computational Drug Discovery Methods. Recorded institutional associations include Novartis (Switzerland), University of Zurich, Hochschule Fresenius.

88Publications
1,823Citations
24H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Changing R&D models in research-based pharmaceutical companies

    2016 · 286 citations
  2. Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension

    2016 · 143 citations
  3. Translational precision medicine: an industry perspective

    2021 · 140 citations
  4. The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects

    2015 · 110 citations
  5. Analysis of pharma R&D productivity – a new perspective needed

    2023 · 88 citations
  6. LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia

    2021 · 72 citations
  7. Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?

    2018 · 68 citations
  8. The upside of being a digital pharma player

    2020 · 62 citations
  9. Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double‐blind, phase 2 trial

    2021 · 57 citations
  10. R&D efficiency of leading pharmaceutical companies – A 20-year analysis

    2021 · 53 citations
  11. Open innovation: A paradigm shift in pharma R&D?

    2022 · 48 citations
  12. Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies

    2025 · 47 citations
  13. Role of Renal Nerves in the Stimulation of the Renin System by Reduced Renal Arterial Pressure

    1999 · 44 citations
  14. Post-translational Serine/Threonine Phosphorylation and Lysine Acetylation: A Novel Regulatory Aspect of the Global Nitrogen Response Regulator GlnR in S. coelicolor M145

    2016 · 43 citations
  15. Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006–2022)

    2025 · 42 citations
  16. T‐type and L‐type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats

    1998 · 36 citations
  17. Big Techs and startups in pharmaceutical R&D – A 2020 perspective on artificial intelligence

    2021 · 33 citations
  18. Investigating the origins of recent pharmaceutical innovation

    2023 · 33 citations
  19. Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure

    2006 · 30 citations
  20. Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation To Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid

    2007 · 28 citations
  21. Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects

    2016 · 27 citations
  22. Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease

    2006 · 26 citations
  23. The significance of blockbusters in the pharmaceutical industry

    2022 · 26 citations
  24. In vitroand clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696)

    2016 · 24 citations
  25. Effect of Steady-State Enoxacin on Single-Dose Pharmacokinetics of Roflumilast and Roflumilast N-Oxide

    2010 · 23 citations

← Return to the university profile